Study of Safety and Tolerability of Intravenous CRS-100 in Adults With Carcinoma and Liver Metastases

Exclusion Criteria

• •1. Known central nervous system metastases.
• •2. History of allergic reactions attributed to sulfa or beta-lactam antibiotics.
• •3. Cardiac conditions associated with high- or moderate-risk of endocarditis.
• •4. Intra-arterial hepatic catheter, hepatic cirrhosis, or clinically relevant ascites.
• •5. Artificial (prosthetic) joint or other artificial implant or devices that cannot easily be removed.
• •6. Known coagulation disorder or recent thromboembolic event.
• •7. Use of immunosuppressive agent, chemotherapy, or radiation therapy within 28 days prior to CRS-100; bone marrow or stem cell transplant or a major organ allograft; autoimmune disease.
• •8. Current history of gallstones or kidney stones.
• •9. Infection with HIV, human t-lymphotropic virus type 1 (HTLV-1), hepatitis c virus (HCV), or hepatitis b virus (HBV).
• •10. Pregnant or lactating